

April 17, 2023

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322 Ref: Scrip Name: GLS

Dear Sirs,

Sub: Reconciliation of Share Capital Audit Report for the Quarter ended March 31, 2023

Enclosed please find herewith the Reconciliation of Share Capital Audit Report issued by M/s. Savita Jyoti Associates, Company Secretaries for the Quarter ended March 31, 2023.

Please take the same on records.

Yours faithfully,
For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary & Compliance Officer

Encl: as above

CS. SAVITA JYOTI, B.Com., F.C.S.

RECONCILIATION OF EQUITY SHARE CAPITAL AUDIT REPORT

1.	. For Quarter Ended			March 31, 2023					
2.	ISIN			INE03Q201024					
3.	Face Value			Rs.2/-					
4.	Name	of the Company		Glenmark Life Sciences Limited					
5.	Regist	ered Office Addres	S	Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur, Maharashtra, 413213					
6.	Correspondence Address			4 th Floor, OIA House, 470, Cardinal Gracious Road, Andheri East Mumbai 400099					
7.	Telephone and Fax Numbers			Tel.: 91 22 68297979 Fax : NIL					
8.	Email Address			complianceofficer@glenmarklifesciences.com					
9.		of the Stock Exch the Company's Se		BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA LIMITED					
				NUMBER OF SHARES % OF TOTAL ISSUED CAPITAL					
10.	Issued Capital				12,25,27,1	72	100%		
11.	Listed Capital				12,25,27,1	72	100%		
12.	Held in Dematerialised form in CDSL				92,70,5	514	7.57%		
13.	Held in Dematerialised form in NSDL		1,132,56,65		92.43%				
14.	Held in	Held in Physical Form		00		0.00			
15.	Total Number of Shares 12+13+14			12,25,27,1	72	2 100%			
16.	Reasons for difference if any, between (10&11), (11&;15)			N.A.					
17.	Certifying the details of changes in share capital during the quarter under consideration as per Table below:								
Part	iculars	No of shares	Applied/ not Applied for Listing	Listed on Stock Exchanges	Whether intimated to CDSL	Whether intimated to NSDL	In-Principle Approval Pending for SE		
1	NIL	NIL	NIL	NIL	NIL	NIL	NIL		

AJ.

SAVITA JYOTI ASSOCIATES

COMPANY SECRETARIES

CS. SAVITA JYOTI, B.Com., F.C.S.

:11:

18.	Register of Members is Updated : If not updated upto which date:								
19.	Reference of previous quarter with regard to excess dematerialized shares, if any:								
20.	Has the Company resolved the matter mentioned in point no.19 above, in the quarter? If not reason why?								
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:								
Tota	No. of Demat Requests	No. of. Requests	No. of Shares	Reasons	s for delay				
Conf	irmed after 21 days	NIL	NIL	NIL					
Pend	ling for more than 21 days	NIL	NIL	NIL					
22.	Name, Telephone & Fax No. of the Compliance Officer of the Company:	Mr. Rudalf Corriea Company Secretary & Compliance Officer Membership No. ACS 27911 Tel: 91 22 68297979; Fax No: NIL							
23.	Name, Address, Telephone & Fax No., Regn. No. of the Practicing Company Secretary:	Mrs. Savita Jyoti Savita Jyoti Associates E-86, Sainikpuri, Secunderabad – 500 094. Telephone No. 040-27110559 Registration No. FCS 3738; CP No: 1796							
24.	Appointment of Common Agency for Share Registry Work : Yes KFin Technologies Limited Tower – B, Plot No 31 & 32, Selenium Building, Financial District, Nanakramguda, Gachibowli, Hyderabad – 500 032, Telangana, India, SEBI registration No: INR000000221 Tel: 040 – 67162222; Fax: 040- 23001153; Email: glenmark.ipo@kfintech.com website: www.kfintech.com								
25.	Any other details that the auditor may like to provide. (e.g. BIFR Company, Delisting from Stock Exchanges, Company changed it name etc.)	NIL							

FOR SAVITA JYOTI ASSOCIATES

SAVITA JYOTI

Place: Hyderabad Date: 13/04/2023

UDIN: F003738E000068761

SAVITA JYOTI, FCS 3738
Practicing Company Secretary
Certificate of Practice No. 1796